Search Results
Preprints with The Lancet

Viewing: 1 - 20 of 709 papers

1.

Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Merryn Voysey
University of Oxford - Oxford Vaccine Group
Sue Ann Costa Clemens
University of Siena - Institute of Global Health
Posted: 01 Feb 2021
Downloads 51,123
2.

Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)

Amy Flaxman
University of Oxford - The Jenner Institute
Natalie Marchevsky
University of Oxford - Oxford Vaccine Group
Posted: 28 Jun 2021
Downloads 6,583
3.

T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study

Adrienn Angyal
University of Sheffield - Department of Infection, Immunity & Cardiovascular Disease
Stephanie Longet
University of Oxford - Wellcome Trust Centre for Human Genetics
Posted: 25 Mar 2021
Downloads 3,410
4.

Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019

Juanjuan Zhao
Zhengzhou University - Department of Hematology
Quan Yuan
Xiamen University - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics
Posted: 03 Mar 2020
Downloads 2,991
5.

Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE Trial

Pamela Kearns
University of Birmingham - NIHR Birmingham Biomedical Research Centre and Institute of Cancer and Genomic Sciences
Stefan Siebert
University of Glasgow
Posted: 23 Aug 2021
Downloads 2,778
6.

Dysregulation of Immune Response in Patients with COVID-19 in Wuhan, China

Chuan Qin
Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Neurology
Luoqi Zhou
Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Neurology
Posted: 02 Mar 2020
Downloads 1,963
7.

Medical Countermeasures Analysis of 2019-nCoV and Vaccine Risks for Antibody-Dependent Enhancement (ADE)

Darrell Ricke
Massachusetts Institute of Technology (MIT) - Lincoln Laboratory
Robert W. Malone
Alchem Laboratories
Posted: 03 Mar 2020
Downloads 1,672
8.

BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian Variant

Helen Marie Parry
University of Birmingham - Institute of Immunology and Immunotherapy
Gokhan Tut
University of Birmingham - Institute of Immunology and Immunotherapy
Posted: 31 Mar 2021
Downloads 1,137
9.

Positive Epstein-Barr Virus Detection in Corona Virus Disease 2019 (COVID-19) Patients

Ting Chen
Wuhan University - Department of Ophthalmology
Jiayi Song
Wuhan University - Renmin Hospital
Posted: 30 Mar 2020
Downloads 885
10.

Antibody Responses After First and Second COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukaemia

Helen Marie Parry
University of Birmingham - Institute of Immunology and Immunotherapy
Graham McIlroy
University of Birmingham - Institute of Cancer and Genomic Sciences
Posted: 25 May 2021
Downloads 824
11.

Multiple Enzyme Release, Inflammation Storm and Hypercoagulability Are Prominent Indicators For Disease Progression In COVID-19: A Multi-Centered, Correlation Study with CT Imaging Score

Haijun Wang
Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Neurosurgery
Shanshan Luo
Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Hematology
Posted: 02 Mar 2020
Downloads 772
12.

Longitudinal Characteristics of Lymphocyte Responses and Cytokine Profiles in the Peripheral Blood of SARS-CoV-2 Infected Patients

Jing Liu
Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Infectious Diseases
Sumeng Li
Huazhong University of Science and Technology - Department of Infectious Diseases
Posted: 19 Feb 2020
Downloads 660
13.

Long-Term Persistence of SARS-CoV-2 Neutralizing Antibody Responses After Infection and Estimates of the Duration of Protection

Eric H.Y. Lau
The University of Hong Kong - WHO Collaborating Centre for Infectious Disease Epidemiology and Control
David S. C. Hui
The Chinese University of Hong Kong (CUHK) - Department of Medicine and Therapeutics
Posted: 07 Jul 2021
Downloads 650
14.

Immunological and Viral Correlates of COVID-19 Disease Severity: A Prospective Cohort Study of the First 100 Patients in Singapore

Barnaby E. Young
National Centre for Infectious Diseases, Singapore
Sean Wei Xiang Ong
National Centre for Infectious Diseases
Posted: 20 May 2020
Downloads 596
15.

Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection

John Frater
University of Oxford - Peter Medawar Building for Pathogen Research
Katie Ewer
University of Oxford - The Jenner Institute
Posted: 19 Apr 2021
Downloads 536
16.

The Potential Role of IL-6 in Monitoring Coronavirus Disease 2019

Tao Liu
Huazhong University of Science and Technology (Formerly Tongi Medical University) - Cancer Center
Jieying Zhang
Huazhong University of Science and Technology (Formerly Tongi Medical University) - Cancer Center
Posted: 10 Mar 2020
Downloads 506
17.

T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study

Adrienn Angyal
University of Sheffield - Department of Infection, Immunity & Cardiovascular Disease
Stephanie Longet
University of Oxford - Wellcome Trust Centre for Human Genetics
Posted: 13 Apr 2021
Downloads 433
18.

Safety and Immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted With CpG 1018 and Aluminum Hydroxide in Healthy Adults: A Phase 1, Dose-Escalation Study

Szu-Min Hsieh
National Taiwan University - Section of Infectious Diseases
Wang-Da Liu
National Taiwan University - Section of Infectious Diseases
Posted: 15 Apr 2021
Downloads 370
19.

Clinical Hallmarks of 13 COVID-19 Patients Revealing SAA Biomarker

Jun Zhang
Baoji Central Hospital
Zhi-Heng Liu
Air Force Medical University - Department of Orthopaedics
Posted: 10 Mar 2020
Downloads 356
20.

Anti-C5a Antibody (IFX-1) Treatment of Severe COVID-19: An Exploratory Phase 2 Randomized Controlled Trial

Alexander P. J. Vlaar
University of Amsterdam - Department of Intensive Care
Sanne de Bruin
Department of Intensive Care, University of Amsterdam, Amsterdam UMC
Posted: 30 Jul 2020
Downloads 346